Melanoma Of Skin clinical trials

Explore recruiting melanoma of skin clinical trials.

Recruiting melanoma of skin studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Melanoma Of Skin trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids. The MEMBRAINS trial

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratification (NivoMela)

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4221023 - A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI−PD-1 THERAPY

Spain, Germany, Slovakia, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

C4221016 - A Phase 3, Randomized, Double-Blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants with BRAF V600E/K Mutation-Positive Metastatic or Unresectable Locally Advanced Melanoma

Italy, Belgium, Poland, Germany, Hungary, Czechia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition

Germany, Spain, France, Belgium, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with metastatic or recurrent melanoma

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Melanoma Of Skin trials by city

Melanoma Of Skin in Toronto Melanoma Of Skin in Vancouver Melanoma Of Skin in Montreal Melanoma Of Skin in Calgary Melanoma Of Skin in Edmonton Melanoma Of Skin in Ottawa Melanoma Of Skin in Winnipeg Melanoma Of Skin in Quebec City Melanoma Of Skin in Hamilton Melanoma Of Skin in Kitchener Melanoma Of Skin in London Melanoma Of Skin in Halifax Melanoma Of Skin in New York Melanoma Of Skin in Los Angeles Melanoma Of Skin in Chicago Melanoma Of Skin in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease